Login
Home
Charts
Search
Watchlist
Products

Sharda Cropchem Ltd

SHARDACROP·NSE
743.95-0.24%Tue, 22 Sept '26 14:02

Sharda Cropchem Ltd

SHARDACROP
NSE
743.95
-0.24%
|Tue, 22 Sept '26 14:02
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
6,706Cr
Close
Close Price
743.30
Industry
Industry
Pesticides/Agrochemicals
PE
Price To Earnings
10.71
PS
Price To Sales
1.25
Revenue
Revenue
5,357Cr
Rev Gr TTM
Revenue Growth TTM
18.52%
PAT Gr TTM
PAT Growth TTM
49.11%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
5816321,3127857779291,8299859291,2892,0651,074
Growth YoY
Revenue Growth YoY%
-19.5-37.8-11.523.133.846.939.425.419.638.712.99.0
Expenses
ExpensesCr
5605631,0577086878151,5257707961,0481,578888
Operating Profit
Operating ProfitCr
21692557790115303215133241487186
OPM
OPM%
3.611.019.49.811.512.316.621.914.318.723.617.3
Other Income
Other IncomeCr
2412-219251253229212235
Interest Expense
Interest ExpenseCr
510100010002
Depreciation
DepreciationCr
7469546569697278768387100
PBT
PBTCr
-341219831464625616986179422118
Tax
TaxCr
-675543155326113310330
PAT
PATCr
-2851432742312041437414531988
Growth YoY
PAT Growth YoY%
-328.3-95.7-27.9130.7253.8571.141.9424.075.3366.056.5-38.4
NPM
NPM%
-4.80.710.93.55.53.411.114.58.011.315.48.2
EPS
EPS
-3.10.515.93.04.73.522.615.88.216.135.39.8
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
5816321,3127857779291,8299859291,2892,0651,074
Growth YoY
Revenue Growth YoY%
-19.5-37.8-11.523.133.846.939.425.419.638.712.99.0
Expenses
ExpensesCr
5605631,0577086878151,5257707961,0481,578888
Operating Profit
Operating ProfitCr
21692557790115303215133241487186
OPM
OPM%
3.611.019.49.811.512.316.621.914.318.723.617.3
Other Income
Other IncomeCr
2412-219251253229212235
Interest Expense
Interest ExpenseCr
510100010002
Depreciation
DepreciationCr
7469546569697278768387100
PBT
PBTCr
-341219831464625616986179422118
Tax
TaxCr
-675543155326113310330
PAT
PATCr
-2851432742312041437414531988
Growth YoY
PAT Growth YoY%
-328.3-95.7-27.9130.7253.8571.141.9424.075.3366.056.5-38.4
NPM
NPM%
-4.80.710.93.55.53.411.114.58.011.315.48.2
EPS
EPS
-3.10.515.93.04.73.522.615.88.216.135.39.8

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1,2221,3991,7071,9982,0032,3963,5804,0453,1634,3205,2685,357
Growth
Revenue Growth%
15.214.522.017.10.319.649.413.0-21.836.621.918.5
Expenses
ExpensesCr
9511,0871,3611,6751,7221,9592,8973,4022,8803,7244,2284,310
Operating Profit
Operating ProfitCr
2713123453222814376836432835961,0401,047
OPM
OPM%
22.222.320.216.114.018.219.115.98.913.819.719.5
Other Income
Other IncomeCr
25161721434629406060142108
Interest Expense
Interest ExpenseCr
105823254223
Depreciation
DepreciationCr
35567099137170245248267275325347
PBT
PBTCr
26127228723518530946443172378856805
Tax
TaxCr
868196592080115894074175179
PAT
PATCr
17519019117616522934934232304681626
Growth
PAT Growth%
41.98.70.2-7.6-6.639.252.4-2.1-90.7854.1123.749.1
NPM
NPM%
14.313.611.28.88.29.69.88.41.07.012.911.7
EPS
EPS
19.421.121.119.618.325.438.737.93.533.775.569.4
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1,2221,3991,7071,9982,0032,3963,5804,0453,1634,3205,2685,357
Growth
Revenue Growth%
15.214.522.017.10.319.649.413.0-21.836.621.918.5
Expenses
ExpensesCr
9511,0871,3611,6751,7221,9592,8973,4022,8803,7244,2284,310
Operating Profit
Operating ProfitCr
2713123453222814376836432835961,0401,047
OPM
OPM%
22.222.320.216.114.018.219.115.98.913.819.719.5
Other Income
Other IncomeCr
25161721434629406060142108
Interest Expense
Interest ExpenseCr
105823254223
Depreciation
DepreciationCr
35567099137170245248267275325347
PBT
PBTCr
26127228723518530946443172378856805
Tax
TaxCr
868196592080115894074175179
PAT
PATCr
17519019117616522934934232304681626
Growth
PAT Growth%
41.98.70.2-7.6-6.639.252.4-2.1-90.7854.1123.749.1
NPM
NPM%
14.313.611.28.88.29.69.88.41.07.012.911.7
EPS
EPS
19.421.121.119.618.325.438.737.93.533.775.569.4

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
9090909090909090909090
Reserves
ReservesCr
7158701,0451,1941,3131,5241,8222,1422,1472,4103,046
Current Liabilities
Current LiabilitiesCr
4696071,0038228561,1391,6921,9711,5811,9862,386
Non Current Liabilities
Non Current LiabilitiesCr
5782899887110139148220238257
Total Liabilities
Total LiabilitiesCr
1,3311,6502,2262,2032,3472,8643,7434,3514,0384,7255,780
Current Assets
Current AssetsCr
9431,1541,5631,5481,6812,0992,8513,2582,9383,5864,438
Non Current Assets
Non Current AssetsCr
3894966636556667658921,0931,1001,1381,342
Total Assets
Total AssetsCr
1,3311,6502,2262,2032,3472,8643,7434,3514,0384,7255,780
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
9090909090909090909090
Reserves
ReservesCr
7158701,0451,1941,3131,5241,8222,1422,1472,4103,046
Current Liabilities
Current LiabilitiesCr
4696071,0038228561,1391,6921,9711,5811,9862,386
Non Current Liabilities
Non Current LiabilitiesCr
5782899887110139148220238257
Total Liabilities
Total LiabilitiesCr
1,3311,6502,2262,2032,3472,8643,7434,3514,0384,7255,780
Current Assets
Current AssetsCr
9431,1541,5631,5481,6812,0992,8513,2582,9383,5864,438
Non Current Assets
Non Current AssetsCr
3894966636556667658921,0931,1001,1381,342
Total Assets
Total AssetsCr
1,3311,6502,2262,2032,3472,8643,7434,3514,0384,7255,780

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
19718117556146246267328341604656
Investing Cash Flow
Investing Cash FlowCr
-120-104-163-360-68-282-208-145-393-510-513
Financing Cash Flow
Financing Cash FlowCr
-89-38132-215-6043-91-97-37-68-118
Net Cash Flow
Net Cash FlowCr
-640-11-10278-29119-894088
Free Cash Flow
Free Cash FlowCr
1961787551146246267328341603655
CFO To PAT
CFO To PAT%
112.295.38.9315.488.8107.576.596.01,069.7198.396.3
CFO To EBITDA
CFO To EBITDA%
72.458.14.9172.652.156.439.151.0120.7101.363.1
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
19718117556146246267328341604656
Investing Cash Flow
Investing Cash FlowCr
-120-104-163-360-68-282-208-145-393-510-513
Financing Cash Flow
Financing Cash FlowCr
-89-38132-215-6043-91-97-37-68-118
Net Cash Flow
Net Cash FlowCr
-640-11-10278-29119-894088
Free Cash Flow
Free Cash FlowCr
1961787551146246267328341603655
CFO To PAT
CFO To PAT%
112.295.38.9315.488.8107.576.596.01,069.7198.396.3
CFO To EBITDA
CFO To EBITDA%
72.458.14.9172.652.156.439.151.0120.7101.363.1

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
2,1064,3933,4573,3599702,5915,5484,4132,8965,1497,8466,706
Price To Earnings
Price To Earnings
12.223.118.119.15.911.315.912.990.916.911.510.7
Price To Sales
Price To Sales
1.73.12.01.70.51.11.61.10.91.21.41.3
Price To Book
Price To Book
2.64.63.02.60.71.62.92.01.32.12.52.1
EV To EBITDA
EV To EBITDA
7.513.710.210.02.95.58.06.610.08.37.36.2
Profitability Ratios
Profitability Ratios
GPM
GPM%
35.835.833.030.530.631.730.129.325.929.935.935.9
OPM
OPM%
22.222.320.216.114.018.219.115.98.913.819.719.5
NPM
NPM%
14.313.611.28.88.29.69.88.41.07.012.911.7
ROCE
ROCE%
32.428.322.419.013.318.423.819.53.415.227.327.3
ROE
ROE%
21.819.816.813.711.714.218.315.31.412.221.721.7
ROA
ROA%
13.211.58.68.07.08.09.37.90.86.411.811.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
2,1064,3933,4573,3599702,5915,5484,4132,8965,1497,8466,706
Price To Earnings
Price To Earnings
12.223.118.119.15.911.315.912.990.916.911.510.7
Price To Sales
Price To Sales
1.73.12.01.70.51.11.61.10.91.21.41.3
Price To Book
Price To Book
2.64.63.02.60.71.62.92.01.32.12.52.1
EV To EBITDA
EV To EBITDA
7.513.710.210.02.95.58.06.610.08.37.36.2
Profitability Ratios
Profitability Ratios
GPM
GPM%
35.835.833.030.530.631.730.129.325.929.935.935.9
OPM
OPM%
22.222.320.216.114.018.219.115.98.913.819.719.5
NPM
NPM%
14.313.611.28.88.29.69.88.41.07.012.911.7
ROCE
ROCE%
32.428.322.419.013.318.423.819.53.415.227.327.3
ROE
ROE%
21.819.816.813.711.714.218.315.31.412.221.721.7
ROA
ROA%
13.211.58.68.07.08.09.37.90.86.411.811.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Sharda Cropchem is an intellectual-property company disguised as a chemicals trader - it does not manufacture anything itself but instead owns the regulatory keys to sell generic crop-protection products in the world’s hardest-to-enter markets. Born in 1987 as a dyes-intermediates proprietorship, the business pivoted decisively when it began spending years patiently identifying molecules coming off patent, compiling scientific dossiers, and winning product registrations in its own name across Europe, North America and Latin America. That registration-first, asset-light approach - buy from regular suppliers, sell to regular customers, but own the licence that makes the sale legal - is the recurring logic behind everything the company does. # Business segments Two engines, one registration-driven and one order-driven - an agrochemical marketing platform built on over 3,000 proprietary licences, and a smaller industrial-supply business that runs on procurement relationships rather than intellectual property. ## 1. Agrochemicals: a registration library that sells crop protection **The company owns the regulatory approvals that let generic fungicides, herbicides and insecticides cross borders; it then sources the chemicals from manufacturers and sells them under its own brand through a network of over 525 distributors.** - **Registrations are the product** - the company identifies molecules approaching patent expiry, prepares dossiers with physicochemical and biological data using GLP-certified labs, and secures marketing approvals in its own name; as of March 2026 it held 3,011 registrations with another 1,004 applications in the pipeline. That library is the barrier to entry, because each registration takes years of scientific and regulatory work before a single litre can be sold. - **Made by others, sold by Sharda** - manufacturing of active ingredients and finished formulations is entirely outsourced to third parties, mostly in China (which supplies 90-95% of procurement) and India for raw materials, and to specialist formulators in Europe and the US for finished products. This saves the capital and time of building plants, so the company can offer a wide range of products and flex with demand. - **Factory-to-farmer distribution** - products reach over 80 countries through more than 525 third-party distributors, supported by a dedicated sales force of over 500 people that the company has been building out in Europe, the US, Canada, Mexico, Colombia, South Africa and India to move closer to end-users. Sales to dealers and distributors made up 95% of total sales in FY25. - **Biocides add a second leg** - the portfolio also includes disinfectants and pest-control products for non-agricultural use, marketed in 39 countries with a focus on Europe and a growing set of registrations. ## 2. Non-agrochemicals: an order-based industrial supply desk **A procurement-and-supply business that sources conveyor belts, dyes and general chemicals from manufacturers in China and India and sells them to channel partners in over 30 countries - no registrations, no proprietary moat.** - **Order-book, not IP** - unlike the agrochemical segment, this business does not depend on regulatory approvals; it is a straight procurement-and-supply operation where the company buys on the back of customer orders and earns a margin on the spread. - **Global reach, lean setup** - the division supplies to more than 30 countries across Europe, North America, Latin America, Australia and Asia, using the same sourcing relationships and logistics backbone that the agrochemical business relies on. # Group structure and partners **A single listed Indian company with a family promoter group and a global web of over 40 subsidiaries that hold registrations and facilitate local market access.** - The company is listed on BSE and NSE, with the promoter group - the Bubna family - holding their entire stake free of any encumbrance as of March 2026. - Chairman and Managing Director Ramprakash V. Bubna, an IIT Bombay chemical engineer with over 58 years in the industry, leads the business; his sons Ashish (agrochemical marketing, procurement and registrations) and Manish (conveyor belts, IT and logistics) serve as whole-time directors. - The company holds a ‘Three Star Export House’ certificate from India’s Directorate General of Foreign Trade, and its statutory auditor is B S R & Associates LLP.

Documents — Sharda Cropchem Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/wyrcm9xi34usq6dehea2myvk.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/v54f9e4x9oo1p4o39oilbvyn.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/e0g0eijwk0q8zdidelikxgyn.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/i162fl9mfr462kt4bny7swoq.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/xi3io17lux951mxvhci10uj1.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/5o5px08afewz7w6iqf06vmbq.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/f8zhr0oo2tw9897b77yg7zl1.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/ei063wfdq5y0uhy33trnjz5t.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/2idt39egqaimox0pavcall88.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/dp2q5owcmrbkk088dehu9hri.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/b030llb47smt0spxplhedxmo.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/ms3gkp5jvc5x8txzp5h4kux7.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/ywhllotxfk1kp7eznigoh9pt.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/mh1vyi871238mwja2ed5jgkh.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/yta97hd074ew3t832lwtutzg.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/4wgsyhiv6jtrn3k0uqezqmdh.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/jn21tnz07hh1afx7rnbbk462.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/y3ebyljrcw3n32paqesqorxk.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/1u82bipcyxqnfeeddl5tfhiv.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/rmxzdrxb3wjabc0i8o8b36v9.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/xh91v9g6nwnsdk9xxtknygve.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/tht5ydrltoaed957v4r9khpc.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/mes3mqomws48br1ayw355v18.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/wzg3sb110gwd7rczk7nxmkzo.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/fyvwt9yjaafzjnja8pwglsvi.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/9am6psitp1umy4f6cynbk16t.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/9iym1iwj6jpwci65e7uqure8.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/mncpuusj2siw5ox1kwavpqob.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/e72xpc592o0nj2jacbzlirat.pdf

Concall Transcript Summaries — Sharda Cropchem Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3ASHARDACROP/transcript-notes/202606/wyrcm9xi34usq6dehea2myvk.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3ASHARDACROP/transcript-notes/202603/v54f9e4x9oo1p4o39oilbvyn.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3ASHARDACROP/transcript-notes/202512/e0g0eijwk0q8zdidelikxgyn.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3ASHARDACROP/transcript-notes/202509/i162fl9mfr462kt4bny7swoq.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3ASHARDACROP/transcript-notes/202506/xi3io17lux951mxvhci10uj1.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3ASHARDACROP/transcript-notes/202503/5o5px08afewz7w6iqf06vmbq.pdf